Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 29, 2011. The report details specific share repurchase and cancellation activities authorized by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes regarding share buybacks and treasury stock.
- Shares Purchased: 1,200,000 Ordinary shares.
- Price Range: Highest price paid was 1,324.5 pence; lowest price paid was 1,310 pence.
- Treasury Shares Cancelled: 30,000,000 Ordinary shares.
- Remaining Treasury Shares: 469,174,284 shares (8.37% of total issued share capital; 9.13% of total voting rights).
- Shares in Issue: 5,136,604,248 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the company's share count through the purchase and subsequent cancellation of 1,200,000 shares, alongside the cancellation of 30,000,000 shares previously held in treasury. These actions reduce the total issued share capital and adjust the proportion of treasury shares held by the company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to shareholder authority and the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the updated total issued share capital and voting rights denominator for disclosure thresholds.
- Confirm the total cost of the 1,200,000 share repurchase based on the weighted average price between 1,310 and 1,324.5 pence.
- Review the impact of the 30,000,000 treasury share cancellation on the company's equity balance sheet.